Wed, Jul 30, 2014, 2:42 PM EDT - U.S. Markets close in 1 hr 18 mins

Recent

% | $
Click the to save as a favorite.

Santarus, Inc. (SNTS) Message Board

  • hofno2003 hofno2003 Sep 30, 2012 2:11 AM Flag

    Remission Rates Ulcerative Colitits: Uceris 17,9% at 9mg, Humira 16%, Humira just approved

    That bodes well for Santarus Uceris. Humira was just approved for ulcerative colitits in US. It demonstrated a remission rate of just 16%-18%, just the same as Uceris demonstrated at 9mg.

    As Humira for sure is the more expensive medication (monoclonal antibody) this is a good indication for the approval of Uceris. Humira and Uceris have both about the same remission rate and the same improvement versus placebo, so the aspect of effectiveness of Uceris is out of question - and it will be approved.

    Humira is now approved for patients if all other therapies failed.

    Here the news release at FDA:

    FDA NEWS RELEASE
    For Immediate Release: Sept. 28, 2012
    Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
    Consumer Inquiries: 888-INFO-FDA

    FDA approves Humira to treat ulcerative colitis

    The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

    Humira is approved to control ulcerative colitis when immunosuppressant medicines like corticosteroids, azathioprine, and 6-mercaptopurine have not worked. The drug is an anti-tumor necrosis factor (TNF) that blocks proteins that play an important role in abnormal inflammatory and immune responses.

    Ulcerative colitis is a chronic disease that causes inflammation and ulcers in the inner lining of the large intestine. It is one of two main forms of chronic inflammatory bowel disease and affects about 620,000 Americans, according to the National Institutes of Health.

    “Each patient with ulcerative colitis experiences the disease differently, and treatment must be adjusted to meet each individual’s needs,” said Donna Griebel, M.D., director of the Division of Gastroenterology and Inborn Errors Products in FDA’s Center for Drug Evaluation and Research. “Today’s approval provides an important new treatment option for patients who have had an inadequate response to conventional therapy.”

    The FDA previously approved Humira to treat rheumatoid arthritis (2002), psoriatic arthritis (2005), ankylosing spondylitis (2006), Crohn’s disease (2007), plaque psoriasis (2008) and juvenile idiopathic arthritis (2008).

    Patients with ulcerative colitis are normally evaluated for stool frequency, rectal bleeding, endoscopic findings and a physician’s #$%$ment, which combined provide a score ranging from 0 to 12 to help #$%$ the activity of ulcerative colitis. This scoring system is commonly referred to as the Mayo score.

    Humira’s safety and effectiveness for ulcerative colitis were established in two clinical studies. A total of 908 patients who had never been treated with a TNF-blocker, or who lost response to or were intolerant to TNF-blockers participated in the studies. All patients enrolled in the studies had a Mayo score of 6 to 12 and an endoscopy subscore of 2 to 3. Patients were randomly assigned to take Humira or a placebo.

    The studies were designed to measure the percentage of patients whose Mayo score decreased to 2 or less with no individual subscore of more than 1 after eight weeks of treatment. Patients who obtained such reductions in the Mayo score were determined to have achieved clinical remission.

    Results from both studies showed 16.5 percent to 18.5 percent of patients treated with Humira achieved clinical remission compared with 9.2 percent to 9.3 percent of patients receiving placebo. Additionally, in the second study, 8.5 percent of patients treated with Humira sustained clinical remission compared with 4.1 percent of patients treated with placebo. The effectiveness of Humira has not been established in patients with ulcerative colitis who have lost response to or were intolerant to TNF blockers.

    The FDA-approved dosing regimen for Humira for ulcerative colitis begins with an initial dose of 160 milligrams, a second dose two weeks later of 80 mg, and a maintenance dose of 40 mg every other week, thereafter. The drug should only continue to be used in patients who have shown evidence of clinical remission by eight weeks of therapy.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Humira is one of the most expensive drugs in the world, the price for one dose is more than 1,000 usd.

      Therefore Humira is no competition for Uceris, Humira is just the proof that remission rates of 16-18% are sufficient for approval.

      Hofno

      Sentiment: Strong Buy

 
SNTS
31.96-0.01(-0.03%)Dec 31 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.